Nausea is the most commonly reported symptom with both treatments, particularly during the dose-escalation phase
This dual GIP and GLP-1 receptor agonist, licensed in the UK for type 2 diabetes and weight management, commonly causes gastrointestinal side effects such as nausea, diarrhoea, and constipation due to its effects on gut motility
If you experience signs of pancreatitis (severe abdominal pain radiating to the back), allergic reactions, or significant kidney issues (often related to dehydration), stopping is the right call
Vitamin supplements reduce the chances of building homocysteine associated with stress
Everyone eventually reaches a weight loss plateau at the maximum tolerated dose of GLP-1 treatment
The movement of these valves transfers blood in contrast to gravity